· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
GlaxoSmithKline
7333 Mississauga Road North
Mississauga, Ontario
Canada L5N 6L4
April 15, 2005
Subject: Products Manufactured at GSK's Cidra, Puerto Rico Facility
Dear Health Care Professional,
GlaxoSmithKline Inc. (GSK), following discussions with Health Canada, would like to advise you of findings from inspections at GSK's manufacturing plant in Cidra, Puerto Rico. It is important to note these findings present an extremely low risk to patients and patients should be advised to continue to take these medications as directed. Two primary issues have been identified:
Inspection by the US Food and Drug Administration has identified manufacturing issues with Paxil CR (paroxetine hydrochloride controlled release tablets) and Avandamet (rosiglitazone maleate/metformin hydrochloride) tablets. One of the findings was that a very small number of Paxil CR tablets could split. Although all products have been sorted and split tablets have been removed, there is a remote possibility that patients could receive a portion of a tablet that lacks active ingredient, or alternatively a portion that contains active ingredient and does not have the intended controlled-release effect. Another finding was that some Avandamet tablets may not have a uniform amount of rosiglitazone, one of the active ingredients in this product.
GSK and Health Canada do not believe these findings pose a significant health risk. GSK has performed additional testing on these products, and along with Health Canada are taking ongoing measures to monitor quality as they are made available in Canada.
There is a very remote possibility that bottles or blister packs of Avandamet, Avandia (rosiglitazone maleate), Coreg (carvedilol), Paxil (paroxetine hydrochloride), Paxil CR or Relafen (nabumetone) may contain a stray tablet of another medication. GSK wants to emphasize that in Canada, there have been no reported incidents of manufacturing issues causing stray tablets of another medication to be found in a bottle or blister pack of the above listed products. However, if a patient were to ingest a stray tablet of an unintended medication, there is a possibility this could cause an adverse reaction. Most of these reactions should be mild and transient. However, there is the possibility a more serious reaction can occur. For example, if an asthmatic patient were to receive a dose of Coreg, severe bronchospasm could occur.
Therefore, as an added precaution, until further notice, GSK asks all pharmacies that use automatic dispensers (counting machines) to either manually dispense or visually inspect these products (see table below) before providing them to their patients. There are significant differences in colour and shape between these products and patients should be advised to check the appearance of their medications before taking them and immediately contact their pharmacist and/or physician if they notice any differences.
In the unlikely event that a pharmacist or any pharmacy personnel should discover a tablet of a different shape, size or colour than the medication being dispensed, he or she should contact the Customer Service Department of GSK at 1-800-387-7374 immediately.
| Product | Strength | DIN |
|---|---|---|
| Avandamet Tablets | 1 mg/500 mg | 02247085 |
| Avandamet Tablets | 2 mg/1000 mg | 02248440 |
| Avandamet Tablets | 2 mg/500 mg | 02247086 |
| Avandamet Tablets | 4 mg/1000 mg | 02248441 |
| Avandamet Tablets | 4 mg/500 mg | 02247087 |
| Avandia Tablets | 2 mg | 02241112 |
| Avandia Tablets | 4 mg | 02241113 |
| Avandia Tablets | 8 mg | 02241114 |
| Coreg Tablets | 3,125 mg | 02229650 |
| Coreg Tablets | 6,25 mg | 02229651 |
| Coreg Tablets | 12,5 mg | 02229652 |
| Coreg Tablets | 25 mg | 02229653 |
| Paxil Tablets | 10 mg | 02027887 |
| Paxil Tablets | 20 mg | 01940481 |
| Paxil Tablets | 30 mg | 01940473 |
| Paxil CR Tablets | 12,5 mg | 02248503 |
| Paxil CR Tablets | 25 mg | 02248504 |
| Relafen Tablets | 500 mg | 02083531 |
| Relafen Tablets | 750 mg | 02083558 |
Please be assured that GSK is working with Health Canada to resolve these issues as quickly as possible. GSK remains committed to product quality and patient safety, and we regret any inconvenience this temporary situation may cause. Should you have any further questions, please contact GSK Customer Service at 1-800-387-7374.
The identification, characterization and management of drug-related adverse events are dependent on the active participation of health-care professionals in adverse drug reaction reporting programs. Healthcare professionals are asked to report any suspected adverse reactions in patients receiving Avandamet, Avandia, Coreg, Paxil, Paxil CR and Relafen directly to GSK or Health Canada at the following addresses:
GlaxoSmithKline Inc.
7333 Mississauga Road North
Mississauga, Ontario
L5N 6L4
Tel: 1-800-387-7374
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
For other inquiries: please refer to contact information.
Drug Compliance Verification & Investigation Unit
DCVIU_UVCEM@hc-sc.gc.ca
Tel/Tél: (613) 941-3967
Fax/Télé: (613) 952-9805
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
Sincerely,
original signed by
Dr. John A Dillon, MB, BCh, MFPM
Vice-President, Research & Development and Chief Medical Officer
GlaxoSmithKline Inc.